Little Green Pharma Ltd (LGP.AX)

Little Green Pharma Ltd (LGP.AX) — VMCI valuation read

Little Green Pharma Ltd (LGP.AX) carries a VMCI composite of 54/100, 4 points above the Healthcare sector median of 50. Among mid-cap names, that gap places LGP.AX in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The LGP.AX insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads LGP.AX trades at 16.0x earnings, 11% below the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of 1.8x is the rate-sensitivity line to watch, the line to track on Little Green Pharma Ltd's next 10-Q.

LGP.AX fell 1.2% over the trailing 7 days, with a +5.0% read on a 30-day basis.